Alteration of Coagulation Test Results and Vaginal Bleeding Associated With the Use of Feverfew (Tanacetum parthenium)

Khalidah A. Alenzi², ³, Fasil H. Alharbi², Fasil M. Tawhara², Ghada S. Fradeesb

Abstract

Tanacetum parthenium (feverfew) is a member of the daisy family; it is used to prevent and treat migraine and rheumatoid arthritis. It has a long history of use as a traditional and folk medicine in Chinese, Greek, Indian and Arabic medicine, having been used for hundreds of years. The term feverfew comes from the Latin word febrifugia and means fever reducer. However, Short term use of feverfew (up to 4 months) is considered safe in adults. According to a few clinical trials, Tanacetum parthenium was not associated with serious adverse events but rather with mild and reversible events. Adverse events leading to withdrawals were mainly of a gastrointestinal nature. There is no major safety issue. Nevertheless, we report one case of a 36-year-old woman with known migraine who visited the obstetrics and gynecology clinic upon developing vaginal bleeding, prolonged duration of the menstrual cycle, and reddish skin without bruising. The patient suffered from these symptoms over a period of 3 months prior to the clinic visit. Based on history, the patient began taking 800 mg capsules of feverfew three times per day 9 months ago. We applied the Naranjo scale in our case, and it indicated that a probable adverse drug reaction probability scale

Keywords: Tanacetum parthenium; Feverfew; Vaginal bleeding; Migraine; Naranjo adverse drug reaction probability scale

Introduction

Tanacetum parthenium has an interesting history. It is a member of the daisy family, and the plant originated in Europe, North America and Australia. According to a few clinical trials, Tanacetum parthenium was not associated with serious adverse events but rather with mild and reversible events [1]. Adverse events leading to withdrawals were mainly of a gastrointestinal nature [1]. There is no major safety issue. Nevertheless, we report one case of a 36-year-old woman with known migraine who visited the obstetrics and gynecology clinic upon developing vaginal bleeding, prolonged duration of the menstrual cycle, and reddish skin without bruising. The patient suffered from these symptoms over a period of 3 months prior to the clinic visit. Based on history, the patient began taking 800 mg capsules of feverfew three times per day 9 months ago. We applied the Naranjo scale in our case, and it indicated that a probable relationship exists between feverfew and vaginal bleeding. Feverfew should be used cautiously by patients planning elective surgery, having coagulant disorders or taking antithrombotic drugs.

Case Report

A 36-year-old female visited the obstetrics and gynecology clinic with complaints of vaginal bleeding, a prolonged dura-
tion of the menstrual cycle exceeding 15 days and reddish skin without bruising. The patient suffered from these symptoms over a period of 3 months prior to the clinic visit.

Physical, colposcopic and hysteroscopy examinations showed no signs of fibroids, adenomyosis, endometritis, hyperplasia or pelvic infection with normal uterine and urethral structure and negative cervix and uterus biopsies.

The laboratory results showed a normal complete blood count (CBC) but a low hemoglobin level of 10 g/dL, a partial thromboplastin time (PTT) of 42 s, a prothrombin time (PT) of 27.3 s, a negative urine pregnancy test and no serum beta human chorionic gonadotropin (hCG).

The patient was a mother of three children and did not have any chronic diseases, blood disorders or polycystic ovary syndrome. The patient had no previous history of miscarriage or ectopic pregnancy, and she had a with a normal hormone profile. She suffered from chronic migraine without auras since the age of 28 years and was treated with 100 mg sumatriptan tablets for 4 years, but without response or improvement, she then changed to topiramate 50 mg once daily. Nine months ago, 800 mg feverfew capsules were administered twice daily for 6 months alone, and then the dose was increased to 800 mg three times daily without improvements.

Previously, she did not take any over-the-counter oral contraceptives or herbs except the combination of paracetamol and caffeine 1 g when needed during feverfew therapy. Feverfew was discontinued, and the doctor prescribed 10 mg medroxyprogesterone tablets for 10 days beginning on the 21st day of the next menstrual cycle with 190 mg iron sulfate tablets twice daily and multivitamin tablets once daily for 3 months.

After 4 months, a workup at the obstetrics and gynecology clinic was performed. The laboratory results showed a PT of 14.4 s, a PTT of 29 s, a hemoglobin level of 12 g/dL, and all coagulation profiles completely recovered to normal levels (Table 1).

### Discussion

Feverfew treats migraine headaches through many mechanisms, and the active constituent parthenolide is a potent inhibitor of polymorphonuclear leukocyte granules, serotonin 5-hydroxytryptamine (5-HT) receptors and prostaglandin synthetase [5]. The dose of feverfew for migraine headaches is 100 to 300 mg up to four times daily for 16 weeks from the standard preparation (0.2-0.4% parthenolide) and 6.25 mg, three times daily, for up to 16 weeks from feverfew supplements with CO₂ extracted [5].

However, the adult dose of parthenolide was 0.2 - 0.6 mg for migraine prophylaxis. According to clinical trials, the beneficial effects of *Tanacetum parthenium* for migraine prophylaxis can be seen within 4 - 6 weeks of initiating therapy. The duration of treatment will vary for individual migraine sufferers [8].

In 2004, a systemic review published in the Cochrane database assessed the evidence against the efficacy of feverfew for preventing migraine and found that the efficacy of feverfew could not be established [1].

Moreover, we used the Naranjo algorithm. It is the most commonly used tool to assess adverse drug reaction causality. This algorithm has ten simple questions. The questions involve the following areas: the temporal relationship, the pattern of response, dechallenge or administration of an antagonist, rechallenge, alternative causes, placebo response, drug level in the body fluids or tissue, dose-response relationship, previous patient experience with the drug, and confirmation by any other objective evidence. The answer to each question is then assigned a score. A score of 9 or greater means that an adverse drug reaction (ADR) is highly probable, a score of 5 to 8 means that an ADR is probable, a score of 1 to 4 means that an ADR is possible, and a score of zero or less means that an ADR is unlikely [4, 13]. We applied this algorithm in our case. The causality rating for feverfew fell within the range of 5 - 8, which indicates a probable ADR. A probable ADR means the event had a plausible time relationship with feverfew intake, and the response to withdrawal (dechallenge) was clinically reasonable with an unknown rechallenge (Table 2).

In our case, a positive dechallenge refers to the adverse drug reaction disappearing after stopping feverfew use, and the patient coagulation profile was improved after 4 months. According to the patient history, physical examination and laboratory investigations, we excluded all possible and alternative causes that could induce vaginal bleeding, e.g., pelvic infections, endometritis and hyperplasia or abnormalities in uterine structure.

In addition, the patient did not take any hormone replacement therapy or oral contraceptives, and these medications can alter coagulation factors. However, a study showed that factor VII and X levels and fibrinogen were significantly increased in patients treated with combined oral contraceptive pills, where the extent of elevation varied depending on the estrogen-progesterone components [14].

During feverfew therapy, the patient took only a combination tablet of paracetamol with caffeine. Paracetamol has scarce inhibition of peripheral cyclooxygenase; it is only a weak inhibitor of platelet aggregation and does not alter the bleeding time [15]. One study did not find an effect of abstinence from caffeine on blood clot lysis time, whereas the effects of caffeine intake on platelet activity are more variable [16].

The vaginal bleeding induced by feverfew in this case

### Table 1. Laboratory Results

| Test                              | First test | After 4 months | Normal range |
|-----------------------------------|------------|----------------|--------------|
| Prothrombin time (s)              | 27.3       | 14.4           | 11 - 16      |
| Partial thromboplastin time (s)   | 42         | 29             | 18 - 28      |
| Hemoglobin (g/dL)                 | 10         | 12             | 12 - 15.5    |
may be related to inhibiting ADP, thrombin, and the collagen-induced aggregation of platelets by interfering with cellular phospholipases, preventing the release of arachidonic acid and inhibiting the release of serotonin from platelets [3, 8]. Feverfew should be used cautiously by patients planning elective surgery or taking parenteral or oral anticoagulants [3, 12].

In our case, the patient received feverfew 800 mg twice daily for 6 months and then increased to 800 mg three times daily. The severity of vaginal bleeding may be related to an increase in the frequency of feverfew and the prolonged duration of use. The treating doctor prescribed medroxyprogesterone to control bleeding and corrected hemoglobin levels with iron supplementation.

**Conclusions**

The efficacy of feverfew for preventing migraine has still not been established. Any patient on *Tanacetum parthenium* should be monitored for blood coagulation factors, and it should be used cautiously by patients planning elective surgery or taking antithrombotic drugs or having coagulant disease. Patients should be advised to taper then discontinue feverfew completely at least 2 - 3 weeks before surgery. The Naranjo scale indicates that a probable relationship exists between feverfew, vaginal bleeding and alterations of coagulation test results.

**Acknowledgments**

The authors would like to thank Dr. Tariq Abdulkareem Al-Rashdan, the obstetrics/gynecology consultant at King Khalid Hospital, Tabuk, Saudi Arabia.

**Financial Disclosure**

None to declare.

**Table 2. The Naranjo Adverse Drug Reaction Probability Scale**

| The Naranjo adverse drug reaction probability scale                                                                 | Yes | No | Do not know | Scale |
|------------------------------------------------------------------------------------------------------------------------|-----|----|-------------|-------|
| Are there previous conclusive reports on this reaction?                                                                | +1  | 0  | 0           | 0     |
| Did the adverse event occur after the suspected drug was administered?                                                  | +2  | -1 | 0           | 2     |
| Did the adverse reaction improve when the drug was discontinued, or a specific antagonist was administered?          | +1  | 0  | 0           | 1     |
| Did the adverse reaction reappear when the drug was readministered?                                                    | +2  | -1 | 0           | 0     |
| Are there alternative causes (other than the drug) that could have on their own caused the reaction?                   | -1  | +2 | 0           | 2     |
| Did the reaction reappear when a placebo was given?                                                                   | -1  | +1 | 0           | 1     |
| Was the blood detected in the blood (or other fluids) in concentrations known to be toxic?                            | +1  | 0  | 0           | 0     |
| Was the reaction more severe when the dose was increased or less severe when the dose was decreased?                   | +1  | 0  | 0           | 1     |
| Did the patient have a similar reaction to the same or similar drugs in any previous exposure?                         | +1  | 0  | 0           | 0     |
| Was the adverse event confirmed by any objective evidence?                                                            | +1  | 0  | 0           | 1     |
| Total                                                                                                                 |     |    |             | 8     |

**Conflict of Interest**

The authors declare that there is no conflict of interest related to the manuscript, including commercial, personal, political, and intellectual aspects.

**Informed Consent**

The patient’s informed consent for publication of this case report was obtained.

**Author Contributions**

All authors shared the entire content of the manuscript including data collection, discussion, writing and editing assistance.

**Data Availability**

The authors declare that data supporting this study’s findings are available within the case report.

**References**

1. Wider B, Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev. 2015;4:CD002286.
2. Gruenwald J, Brendler T, Jaenicke C. PDR for herbal medicines: Thomson Reuters. 2007.
3. Kemper KJ. Feverfew (*Tanacetum parthenium*). 2007.
4. Baranov D. Everything you need to know about feverfew and migraines. Prima. 1999.
5. Pareek A, Suthar M, Rathore GS, Bansal V. Feverfew (*Tanacetum parthenium L.)*: A systematic review. Pharmacogn Rev. 2011;5(9):103-110.
6. Setty AR, Sigal LH. Herbal medications commonly
used in the practice of rheumatology: mechanisms of action, efficacy, and side effects. Semin Arthritis Rheum. 2005;34(6):773-784.
7. Cardenas J, Reyes-Perez V, Hernandez-Navarro MD, Dorantes-Barron AM, Almazan S, Estrada-Reyes R. Anti-inflammatory and antidepressant-like effects of an aqueous extract of Tanacetum parthenium L. Schultz-Bip (Asteraceae) in mice. J Ethnopharmacol. 2017;200:22-30.
8. Asiri YA. The ABC clinical guide to herbs. King Faisal Specialist Hospital & Research Centre. 2004.
9. Clocon JO, Clocon DG, Galindo DJJG. Botanicals can affect surgical outcomes and follow-up. 2004:59.
10. Baldwin C, Anderson L, Phillipson JJPJ. What pharmacists should know about ginseng? 1986;237:583-586.
11. Pugh WJ, Sambo K. Prostaglandin synthetase inhibitors in feverfew. J Pharm Pharmacol. 1988;40(10):743-745.
12. Berman BM. Complementary medicine and medical education. BMJ. 2001;322(7279):121-122.
13. Doherty MJ. Algorithms for assessing the probability of an adverse drug reaction. Respir Med CME. 2009;2:63-67.
14. Norris LA, Bonnar J. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives. Br J Obstet Gynaecol. 1996;103(3):261-267.
15. Pini LA, Guerzoni S, Cainazzo M, Ciccarese M, Prudenzano MP, Livrea P. Comparison of tolerability and efficacy of a combination of paracetamol + caffeine and sumatriptan in the treatment of migraine attack: a randomized, double-blind, double-dummy, cross-over study. J Headache Pain. 2012;13(8):669-675.
16. Lee KW, Lip GY. Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. Arch Intern Med. 2003;163(19):2368-2392.